AstraZeneca’s Real-World Study on Acalabrutinib in Romania: Key Insights for Investors

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is conducting a study titled ‘Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania.’ The study aims to evaluate the real-world outcomes of acalabrutinib in patients with chronic lymphocytic leukemia (CLL) in Romania, focusing on the time to treatment discontinuation and other clinical characteristics.

The intervention being tested is acalabrutinib, a drug approved by the European Medicines Agency for CLL treatment. It is used either alone or in combination with obinutuzumab, targeting both untreated and previously treated patients.

This observational study follows a cohort model with a retrospective time perspective. It involves secondary data collection from 250 patients over three years, divided into two cohorts based on the year of acalabrutinib initiation.

The study began on December 13, 2023, with an estimated completion date in 2026. The last update was submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.

The study’s findings could impact AstraZeneca’s stock performance by providing insights into acalabrutinib’s effectiveness in real-world settings, potentially influencing investor sentiment. As the CLL treatment landscape evolves, competitors may also be affected by these results.

The study is ongoing, with further details available on the ClinicalTrials portal.